manufacturing facility located in Rancho Bernardo, California. The
Company had leased the 94,000-square-feet facility since late 1997.
The transaction is expected to have an immaterial effect on
Gen-Probe's income statement in 2008, but is expected to be accretive
to earnings over the long term, based on rent increases that would
have been associated with renewing the Company's lease. "The purchase
of our state-of-the-art blood screening manufacturing facility on
attractive financial terms reflects our long-term commitment to
providing innovative nucleic acid tests that safeguard the world's
supply of donated blood," said Mr. Hull.
Webcast Conference Call
A live webcast of Gen-Probe's fourth quarter 2007 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (800) 308-7858 for domestic callers and (402) 220-3841 for international callers.
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.
APTIMA, APTIMA COMBO 2, PACE and TIGRIS are trademarks of Gen-Probe.
ULTRIO and P
|SOURCE Gen-Probe Incorporated|
Copyright©2008 PR Newswire.
All rights reserved